<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749071</url>
  </required_header>
  <id_info>
    <org_study_id>CS-100</org_study_id>
    <nct_id>NCT02749071</nct_id>
  </id_info>
  <brief_title>An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EndoStim Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EndoStim Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to demonstrate the safety and effectiveness of Lower
      Esophageal Sphincter (LES) Stimulation System in treating gastroesophageal reflux disease
      (GERD). This investigation is a multicenter, randomized, double-blind, sham-controlled study.
      After the implant procedure, subjects will be randomized to either the Treatment Group
      (immediate stimulation) or Control Group (delayed stimulation) for six months followed by an
      additional open-label phase in which all subjects will receive electrical stimulation.
      Subjects continue on stimulation treatment in an extended open-label follow-up phase through
      5 years post-stimulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this investigation is to demonstrate the safety and effectiveness of the
      EndoStim® Lower Esophageal Sphincter (LES) Stimulation System in the treatment of subjects
      with gastroesophageal reflux disease (GERD). This investigation is a multicenter, randomized,
      double-blind, sham-controlled clinical investigation. After the implant procedure, subjects
      will be randomized to either the Treatment Group (immediate stimulation) or Control Group
      (delayed stimulation) for a 6-month, double-blind phase followed by an additional open-label
      treatment phase in which all subjects will receive electrical stimulation therapy for a total
      of 12 months. Subjects continue on stimulation treatment and an extended open-label follow-up
      phase includes an 18 month post-stimulation phone interview followed by annual visits through
      5 years post-stimulation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of device and/or procedure-related serious adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of occurrence of device and/or procedure-related serious adverse events after 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects achieving pH success (pH&lt;4 for mo more than 5.3% of time or at least 50% improvement in pH compared to baseline)</measure>
    <time_frame>Comparison of 6 months to baseline data</time_frame>
    <description>Comparison between treatment and control group: percentage of subjects achieving pH success ((pH&lt;4 for mo more than 5.3% of time or at least 50% improvement in pH compared to baseline)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Gastroesophageal Reflux Disease (GERD)</condition>
  <condition>Reflux, Gastroesophageal</condition>
  <condition>Gastroesophageal Reflux</condition>
  <condition>Acid Reflux</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will undergo laparoscopic implantation surgery. The device will not be activated: Sham EndoStim stimulation for first six months of study. It will be activated at the Month 6 visit and provide lower esophageal stimulation from Month 6 thru end of study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group will undergo laparoscopic implantation surgery. The device will be activated two weeks post-implantation and the subject will receive EndoStim stimulation for first six months of study and continue with EndoStim stimulation from Month 6 thru end of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic implantation surgery</intervention_name>
    <description>Laparoscopic surgery to implant the pulse generator and bipolar lead.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoStim stimulation for first six months of study</intervention_name>
    <description>Lower esophageal stimulation</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>EndoStim Implantable Pulse Generator (IPG)</other_name>
    <other_name>lower esophageal stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoStim stimulation from Month 6 thru end of study</intervention_name>
    <description>Lower esophageal stimulation</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>EndoStim Implantable Pulse Generator (IPG)</other_name>
    <other_name>lower esophageal stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham EndoStim stimulation for first six months of study</intervention_name>
    <description>EndoStim device remains &quot;off&quot; (no stimulation delivered)</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able and willing to provide written informed consent

          2. Able and willing to comply with required study procedures and follow-up schedule

          3. 22 - 75 years of age at the time of informed consent

          4. Documented symptoms of gastroesophageal reflux disease (GERD) for longer than 6 months
             (regurgitation and/or heartburn which is defined as burning epigastric or substernal
             pain which responds to acid neutralization or suppression) which requires daily use of
             proton pump inhibitors (PPIs) or other anti-reflux drug therapy, who continue to have
             symptoms despite maximum medical therapy or are &quot;intolerant&quot; -severe side-effects
             (e.g. anaphylaxis or severe allergic reaction, recurrent C. difficile, severe
             hypomagnesaemia) to one PPI or mild/moderate side effect (e.g. nausea, vomiting,
             diarrhea or abdominal pain) to at least 2 PPIs of different chemical classes.

          5. Symptomatic improvement on PPI therapy demonstrated by a composite GERD-health-related
             quality of life (HRQL) score of ≥20 off PPI, and a ≥10 point improvement on PPI
             compared to the off PPI composite GERD-HRQL score. Patients who meet the definition
             above of PPI intolerant are not required to have ≥10 point improvement. The on-PPI
             score to satisfy this criterion will be the score from the GERD-HRQL assessment
             completed after resuming PPIs following the Baseline visit.

          6. Excessive lower esophageal acid exposure during pH monitoring (defined as distal
             esophageal pH &lt; 4 for &gt; 6.0% of the monitoring time) performed after at least 5 days
             off of PPIs and at least 2 days off of H2 blockers. At least 18 hour of esophageal pH
             recording will be considered adequate and inclusion will be based on the day (at least
             18 hours of valid data) with the highest acid exposure percentage time.

          7. Esophagitis ≤ Grade B (Los Angeles (LA) classification) as measured by upper endoscopy
             off PPI and H2 blockers for 10-14 days

          8. Esophageal body contraction amplitude &gt; 30 mmHg for &gt; 30% of swallows and &gt; 30%
             peristaltic contractions on HRM or ≥ 30% peristaltic contractions with DCI &gt;450.

          9. Suitable surgical candidate able to undergo general anesthesia and laparoscopic
             surgery

        Exclusion Criteria:

          1. Previous EndoStim LES System implant and/or implant attempt

          2. Previous surgery involving the gastroesophageal junction or the lead implant site,
             such as a Nissen fundoplication

          3. Previous endoscopic intervention for the treatment of GERD and/or Barrett's esophagus

          4. Hiatal hernia larger than 3 cm as determined by endoscopy

          5. History of gastroparesis

          6. Any non-GERD esophageal motility disorders that in the opinion of investigator
             precludes an anti-reflux procedure

          7. History of or known esophageal stricture or significant esophageal anatomic
             abnormalities (obstructive lesions, etc.)

          8. Barrett's esophagus or any grade of dysplasia

          9. Documented history of esophagitis Grade C or D (LA Classification)

         10. History of suspected or confirmed esophageal or gastric cancer

         11. Esophageal or gastric varices

         12. Symptoms of dysphagia more than once per week every week within the last 3 months

         13. Unable to tolerate withdrawal from H2 Blockers or PPI medications

         14. Suspected or known allergies to titanium, platinum, iridium, stainless steel,
             silicone, epoxy, or nylon

         15. Body mass index (BMI) &gt; 35 kg/m2

         16. Any significant multisystem diseases

         17. Autoimmune or a connective tissue disorder (scleroderma, dermatomyositis,
             Calcinosis-Raynaud's-Esophagus Sclerodactyly Syndrome (CREST), Sjogren's Syndrome,
             Sharp's Syndrome, etc.) requiring therapy in the preceding 2 years

         18. Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (T2DM) defined as
             HbA1c &gt; 9.5 in the previous 6 months or at screening/baseline

         19. Significant cardiac arrhythmia or ectopy or significant cardiovascular disease (i.e.
             unstable angina pectoris, hemodynamically significant valvular disease, severe
             congestive heart failure), or any cardiac therapeutic intervention within the last 6
             months.

         20. Significant cerebrovascular event within the last 6 months

         21. Existing implanted electrical stimulator (pacemaker, implantable cardioverter
             defibrillator, deep brain stimulator (DBS), bone growth or pelvic floor stimulators,
             drug pumps, etc.)

         22. Female subject of child-bearing potential and is pregnant or nursing, or intends to
             become pregnant during the trial period, who is not using a reliable form of birth
             control

         23. Currently enrolled in other potentially confounding research

         24. Active infection as determined by the investigator

         25. History of any malignancy, other than basal cell carcinoma, in the last 2 years

         26. Life expectancy less than 3 years aa. Diagnosed major psychiatric disorder (bipolar,
             schizophrenia, etc.) bb. Any condition that, at the discretion of the investigator or
             sponsor, would interfere with accurate interpretation of the study endpoints or
             preclude participation in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas J Shaheen, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie Uribe</last_name>
    <email>duribe@endostim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veta Clayton, RN, CCRC</last_name>
      <phone>602-406-5853</phone>
      <email>veta.clayton@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Ross Bremner, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sumeet Mittal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Chee</last_name>
      <email>GIresearch@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>James Swain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akshay Shah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Reynoso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California (USC)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pui Yan</last_name>
      <phone>323-422-3426</phone>
      <email>puiyan@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Edy E Soffer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John C Lipham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Center for Clinical Research</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divya Pathak</last_name>
      <phone>650-721-8436</phone>
      <email>divya22@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John Clarke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Morton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SOFI Center for Esophageal Wellness</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Heidrick, CRC</last_name>
      <phone>303-788-1636</phone>
      <email>rachel@sofisite.com</email>
    </contact>
    <investigator>
      <last_name>Reginald CW Bell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Montera, RCMA</last_name>
      <phone>813-844-7948</phone>
      <email>bmontera@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Vic Velanovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Richter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell University Weill Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzan Rosen, NP</last_name>
      <phone>212-746-4014</phone>
      <email>sur9056@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Felice Schnoll-Sussman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip Katz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Sanchez</last_name>
      <phone>212-305-3009</phone>
      <email>as5546@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lyn Goldsmith, RN</last_name>
      <email>lg2240@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Bessler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria Sheen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Markowitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah McGee</last_name>
      <phone>919-966-4591</phone>
      <email>smcgee@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas J Shaheen, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy M Farrell, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meredith C Duke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evan S Dellon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas HealthCare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Standridge, RN</last_name>
      <phone>704-304-7109</phone>
      <email>susan.standridge@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Steven Teich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Colavita, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Scobey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The MetroHealth System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronnie Fass, MD</last_name>
      <phone>216-778-5736</phone>
    </contact>
    <investigator>
      <last_name>Ronnie Fass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Brandt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Grimes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Suzo</last_name>
      <phone>614-293-9964</phone>
      <email>andrew.suzo@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Kyle A. Perry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey W. Hazey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nick DeRose</last_name>
      <phone>503-935-8379</phone>
      <email>nderose@orclinic.com</email>
    </contact>
    <investigator>
      <last_name>Christy Dunst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven DeMeester, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Reavis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lee Swanstrom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlie Borzy</last_name>
      <phone>503-494-4949</phone>
      <email>borzyj@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>John Hunter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Dolan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily J. Smith, BA</last_name>
      <phone>412-578-1378</phone>
      <email>Emily.J.Smith@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Blair A. Jobe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fahim A. Habib, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toshitaka Hoppo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoshihiro Komatsu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Higginbotham, MPA</last_name>
      <phone>615-322-4643</phone>
      <email>tina.higginbotham@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Vaezi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Hadorn, RN</last_name>
      <phone>512-509-4272</phone>
      <email>Lisa.Hadorn@BSWHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Quezada, CCRP</last_name>
      <phone>512-218-6375</phone>
      <email>Theresa.Quezada@BSWHealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>F. Paul Buckley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jad Khoraki, MD</last_name>
      <phone>804-628-3753</phone>
      <email>jad.khoraki@vcuhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Deantonio</last_name>
      <email>jonathan.deantonio@vcuhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Guilherme M Campos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George B Smallfield, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lieselot Holvoet</last_name>
      <email>lieselot.holvoet@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Vangeel</last_name>
      <email>vanessa.vangeel@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Tim Vanuytsel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans Van Veer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard HERRIOT</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Center Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bas Castelijns</last_name>
      <email>bas.castelijns@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Nicole Bouvy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Conchillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daryl Hagan</last_name>
      <phone>020 7679 9355</phone>
      <email>daryl.hagan.16@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Laurence Lovat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muntzer Mughal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rami Sweis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Borzoueh Mohammadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rehan Haidry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lessgerd.com</url>
    <description>Study website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

